Novo Nordisk NVO

NYSE · Pharmaceutical Preparations
$39.43−3.12%Nov 18 close · Databento
Every report →
TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Revenuekr 309.1B +6.4%
True FCF (ex-SBC)kr 59.0B −20.1%
Rule of 4025.5%
ROIC33.8%
FCF Margin19.1%
EPS, dilutedkr 23.03 +1.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio51%
FCF / sh—
EPS (diluted)kr 23.03
Compounder & Returns
Rule of 4025.5%
ROIC33.8%
Cash ROIC (CROIC)19.8%
GP / Assets46.1%
ROE52.8%
ROA18.9%
Gross Margin81.0%
Oper. Margin41.3%
Net Margin33.1%
FCF Margin19.1%
True FCF Margin19.1%
Quality & Dilution
Cash Conversion58%
Accrual Ratio−3.1%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate94%
Sales Growth Y/Y+6.4%
Sales 3Y CAGR+20.4%
EPS Growth Y/Y+1.8%
FCF Growth Y/Y−20.1%
FCF 3Y CAGR−4.0%
Share Change Y/Y—
Balance Sheet & Scale
Revenue (FY)kr 309.1B
Gross Profit (FY)kr 250.3B
Oper. Income (FY)kr 127.7B
GAAP Net Incomekr 102.4B
True FCF (ex-SBC)kr 59.0B
Cash & Equivkr 26.5B
Total Debtkr 131.0B
Net Cash (Debt)kr -104.5B
Net Cash % MCap—
Debt / FCF (yrs)2.2y
Current Ratio0.80
Price & Technicals (EOD)
Perf Week−4.04%
Perf Month+0.20%
Perf Quarter−14.54%
Perf Half Y−12.51%
Perf YTD−11.17%
SMA 20 Dist−1.95%$40.22
SMA 50 Dist−0.92%$39.80
SMA 100 Dist−9.92%$43.77
Window High−23.60%$51.61
Window Low+5.65%$37.32
RSI (14) · Vol45.235%v
Income Distribution & Cash Flow ConversionHow every dollar of NVO revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%kr 309.1BGROSS PROFIT · 81.0%kr 250.3BCOST OF REV · 19.0%kr 58.8BOPER. INCOME · 41.3%kr 127.7BOPEX · 39.7%R&D kr 52.0B · SG&A kr 6.0BNET INCOME · 33.1%kr 102.4BTAX & OTHER · 8.2%kr 25.2B
Where Every kr 100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)kr 58.8B (kr 19.0 / kr 100)
R&D Reinvestmentkr 52.0B (kr 16.8 / kr 100)
SG&A & Other OpExkr 70.6B (kr 22.8 / kr 100)
Tax & Non-Operatingkr 25.2B (kr 8.2 / kr 100)
Net Profit Keptkr 102.4B (kr 33.1 / kr 100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Incomekr 102.4B (33.1% margin)
Operating Cash Flow (OCF)kr 119.1B(38.5% of rev)
Less: Capital Expenditures−kr 60.1B(19.5% of rev)
Standard Free Cash Flow (FCF)kr 59.0B(19.1% margin)
Less: Stock-Based Comp (SBC)—
True FCF (Owner Cash ex-SBC)kr 59.0B(19.1% of rev)

Operating leverage — margins

GrossOperatingNet
0%45%90%81%41%33%FY21FY22FY23FY24FY25
Unlocked SEC EDGAR Accounting Statements (DKK)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (DKK)FY2021FY2022FY2023FY2024FY2025YoY Δ4Y CAGRTrend
Income Statement
Cost of Revenue (COGS)kr 23.7Bkr 28.4Bkr 35.8Bkr 44.5Bkr 58.8B+32.0%+25.6%
Research & Development (R&D)kr 17.8Bkr 24.0Bkr 32.4Bkr 48.1Bkr 52.0B+8.3%+30.8%
Selling, General & Admin (SG&A)kr 4.0Bkr 4.5Bkr 4.9Bkr 5.3Bkr 6.0B+13.1%+10.2%
Total Operating Expenseskr 58.5Bkr 73.7Bkr 93.9Bkr 117.5Bkr 122.6B+4.3%+20.3%
Interest Expensekr 2.5Bkr 6.0Bkr 845.0Mkr 7.3Bkr 6.8B−7.7%+29.0%
Income Tax Expensekr 11.3Bkr 13.5Bkr 21.0Bkr 26.2Bkr 28.1B+7.3%+25.5%
Balance Sheet
Cash & Equivalentskr 10.7Bkr 12.7Bkr 14.4Bkr 15.7Bkr 26.5B+69.0%+25.4%
Inventorykr 19.6Bkr 24.4Bkr 31.8Bkr 40.8Bkr 49.6B+21.5%+26.1%
Total Current Assetskr 85.6Bkr 108.2Bkr 139.6Bkr 161.8Bkr 172.5B+6.6%+19.1%
Total Assetskr 194.5Bkr 241.3Bkr 314.5Bkr 465.6Bkr 542.9B+16.6%+29.3%
Total Current Liabilitieskr 99.5Bkr 120.9Bkr 169.7Bkr 217.6Bkr 215.7B−0.9%+21.3%
Total Debt (Short + Long Term)kr 26.6Bkr 25.8Bkr 27.0Bkr 102.8Bkr 131.0B+27.4%+48.9%
Total Liabilitieskr 123.8Bkr 157.8Bkr 207.9Bkr 322.1Bkr 348.9B+8.3%+29.6%
Stockholders' Equitykr 70.7Bkr 83.5Bkr 106.6Bkr 143.5Bkr 194.0B+35.2%+28.7%
Net Cash / (Net Debt)kr -15.9Bkr -13.1Bkr -12.6Bkr -87.1Bkr -104.5B−19.9%—
Invested Capitalkr 86.7Bkr 96.6Bkr 119.2Bkr 230.6Bkr 298.5B+29.5%+36.2%
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)—kr 6.6Bkr 7.3Bkr 8.5Bkr 14.7B+71.6%+30.8%
Capital Expenditures (CapEx)kr 6.3Bkr 12.1Bkr 25.8Bkr 47.2Bkr 60.1B+27.5%+75.5%
True FCF (ex-SBC Owner Cash)kr 48.7Bkr 66.7Bkr 83.1Bkr 73.8Bkr 59.0B−20.1%+4.9%
Dividends Paidkr 21.5Bkr 25.3Bkr 31.8Bkr 44.1Bkr 51.8B+17.3%+24.5%

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what NVO did at the next close after each story
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.